Denmark · Delayed Price · Currency is DKK Bavarian Nordic Company Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.
It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Country | Denmark |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,692 |
| CEO | Paul Chaplin |
Contact Details
Address: Philip Heymans Alle 3 Hellerup, 2900 Denmark | |
| Phone | 45 33 26 83 83 |
| Website | bavarian-nordic.com |
Stock Details
| Ticker Symbol | BAVA |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0015998017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | Chief Executive Officer and President |
| Henrik Juuel M.Sc. | Chief Financial Officer and Executive Vice President |
| Russell Thirsk M.Sc. | Executive Vice President and Chief Operating Officer |
| Rolf Sass Sorensen | Vice President of Investor Relations |
| Jean-Christophe May M.B.A., Pharm.D. | Executive Vice President and Chief Commercial Officer |